19 November 2011

TCS: US$2.2 bn deal with Friends Life - good indicator on several counts :: Kotak Sec

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


TCS (TCS)
Technology
US$2.2 bn deal with Friends Life – good indicator on several counts. TCS has
announced a US$2.2 bn TCV 15-year closed life policy administration contract with
Friends Life, a leading UK-based insurance provider. Even as the ACV of the deal at
US$150 mn per annum does not warrant a revision in our estimates, it does provide
additional comfort to our forecasts. More importantly, the deal validates the increasing
participation of large Indian providers in general (and TCS in particular) in large, nonlinear,
complex, multi-year outsourcing contracts. Retain BUY on TCS.

Voltas: Low profitability across segments as PAT led by other income and exceptionals :: Kotak Sec

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


Voltas (VOLT)
Industrials
Low profitability across segments as PAT led by other income and exceptionals.
In-line sales of Rs11 bn though EBITDA was only Rs76 mn (0.7%, excluding other
income). PAT of Rs210 mn (ex-tax adjusted exceptional) was led by higher other income
(Rs421 mn). Decline in sales and margin was across projects (cost overruns in Qatar,
India did better) and products segments. Working capital and debt increased (higher
debtors and lower liabilities). Downgrade to REDUCE (TP: Rs110 vs. Rs135 earlier).

Tata Communications: Good quarter; margin sustainability and cash flow turnaround the key :: Kotak Sec

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


Tata Communications (TCOM)
Telecom
Good quarter; margin sustainability and cash flow turnaround the key. TCOM
reported a solid quarter driven by sharp 420 bps qoq margin expansion despite a
modest revenue miss. Margin expansion was driven by substantial absolute cost
reduction within the core business and strong revenue performance at Neotel, which
turned EBITDA positive during the quarter. We raise estimates substantially. Raise our
SOTP-based target price to Rs200/share (from Rs180). REDUCE rating stays.

Apollo Tyres: India business disappoints; margin outlook positive :: Kotak Sec

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


Apollo Tyres (APTY)
Automobiles
India business disappoints; margin outlook positive. Apollo Tyres’ 2QFY12 results
were below estimates led by subdued India business even as margins (EBIT) expanded
qoq for foreign subsidiaries. Domestic margins (EBITDA) declined qoq (120 bps) as (1)
sales mix shifted in favor of OEs and (2) volumes declined by 10% qoq. Going forward,
outlook on margins is positive as raw material prices have softened. Retain BUY with a
target price of Rs80 (Rs85 earlier).

Jyothy Laboratories: Early signs of turnaround visible :: Kotak Sec

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


Jyothy Laboratories (JYL)
Consumer products
Early signs of turnaround visible. 2QFY12—while JYL’s standalone results were
disappointing, benefits of cost reduction measures were visible in HIL profitability. We
keenly watch for consumer acceptance of the recent price hike of 7% in JYL products.
We remain believers in the JYL story in the long term; however, we continue to expect
significant challenges in JYL’s existing portfolio and integration with HIL. However, most
of the negatives are in the price, in our view. ADD. TP Rs200 (Rs220 earlier).

CESC: Stable returns in power, clarity on retail losses key to stock performance :: Kotak Sec

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


CESC (CESC)
Utilities
Stable returns in power, clarity on retail losses key to stock performance. CESC
reported another quarter of stable earnings from its core power business, with net
income of Rs1.1 bn from its distribution business at Kolkata. We maintain our BUY
rating with a revised target price of Rs400/share—factoring lower availability and higher
cost for coal at CESC’s 600 MW project in Chandrapur. At 0.8X P/B and 6.5X P/E on
FY2013E net worth and earnings, CESC remains a preferred pick among the utility
coverage with extant operation not facing any risk on fuel availability and pricing.

Mahindra Satyam: Currency drives EBITDA/PAT beat even as revenues disappoint :: Kotak Sec

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


Mahindra Satyam (SCS)
Technology
Currency drives EBITDA/PAT beat even as revenues disappoint. Satyam’s 2QFY12
looked good on headline numbers, but disappointed on details. Better-than-expected
average Re/US$ realization and higher other income drove 1.5% EBITDA and 15% net
income beat for 2QFY12 even as US$ revenues missed our estimate by 1.8%. Revised
currency assumptions drive a 13/15% increase in our FY2012/13E EPS estimates. We
raise our target price to Rs80/share (from Rs70) and rating to REDUCE (from SELL).

Cadila Healthcare: Weak quarter as expected, warning letter resolution is key stock trigger :: Kotak Sec

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


Cadila Healthcare (CDH)
Pharmaceuticals
Weak quarter as expected, warning letter resolution is key stock trigger. 2QFY12
was a soft quarter as expected with PAT ex-forex flat yoy, 3% below our estimates
marked by poor growth in India of 7%. While US surprised with strong organic growth
of 26%, most other geographies disappointed with muted growth leading to poor
organic growth of 8%. We reduce our FY2012/13E EPS by 8/4% due to lower sales
growth in Europe, emerging markets, API and forex loss. While we factor in 20%
organic sales growth in US in FY2013E, this is contingent on resolution of warning
letter, which remains the key stock trigger in near term. Maintain REDUCE (unchanged)
with PT at Rs860 (was Rs900), 20X FY2013E EPS of Rs43 (was Rs45).

Glenmark Pharmaceuticals: Lower margin leads to PBT miss, sales growth impressive :: Kotak Sec

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


Glenmark Pharmaceuticals (GNP)
Pharmaceuticals
Lower margin leads to PBT miss, sales growth impressive. While sales were 11%
higher than our estimate, lower EBITDA margin at 20.5% led to PBT adjusted for forex
loss, research income at Rs1.3 bn, up 6% qoq, 10% below our estimates. We reduce
our FY2012E PAT by 6% due to lower margin in 2HFY12E, leave FY2013E largely
unchanged. We estimate EPS (excluding research income, forex) to grow at 17% in
FY2013E to Rs22.6. Maintain ADD with PT at Rs395—15X FY2013E core EPS, at 25%
discount to front-line generics multiple due to balance sheet concerns—debt/equity at
1X, impacted by higher Rupee rate and gross block up by Rs1.5 bn in 1HFY12 with
capex at Rs1 bn, according to the company implying addition to intangibles/CWIP.

Ranbaxy Laboratories: Base business margin still sub 10% :: Kotak Sec

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


Ranbaxy Laboratories (RBXY)
Pharmaceuticals
Base business margin still sub 10%. Operational performance was below
expectations with reported EBITDA 17% lower due to (1) poor sales growth at 10% yoy
and (2) EBITDA margin excluding forex at 8.3%, 80 bps below estimate. We reduce
operational estimates by 11% in 2011E and leave 2012E unchanged. We factor in
significant recovery in base business in 2012E—sales growth at 20% versus 13% YTD
and margin at 12% versus 8% YTD. Despite this, the stock excluding FTF pipeline value
of Rs84/share is trading at 19X 2012E base business EPS. Maintain SELL, PT at Rs435
(unchanged)—(17X 2012E core EPS + FTF pipeline value).

Buy TV18 BROADCAST : TARGET PRICE: RS.65 :: Kotak Sec

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


TV18 BROADCAST LTD
PRICE: RS.44 RECOMMENDATION: BUY
TARGET PRICE: RS.65 FY13E P/E: 46.4X
q TV18 Broadcast results were ahead of our estimates on account of stronger
performance from news channels of the company, which offset (continued)
unexpected losses in the movie business of the company. The
company reported revenues Rs 3020 mn, and PAT (loss)Rs 81 mn for the
quarter. The balance sheet of the company is stable with net debt of Rs
6.8Bn in the quarter (versus Rs 6.7Bn in 1QFY12).
q Weakening advertising environment, intense competition in the Hindi
GEC space, force cuts in our estimates for FY12/ FY13. We believe the
company shall bring in (adjusted) EPS Rs 0.2 in FY12 (prior est: Rs 1.0)/ Rs
0.9 in FY13. As such medium-term profitability outlook has weakened
substantially. The company's decision to defer the launch of a Hindi
movie channel shall also impact the traction that the company can gain
in subscription revenues over the medium to long term. We cut our longterm
assumptions on subscription revenues of the company, and estimate
the fair value of the stock at Rs 65 (Rs 78 earlier).
q Even so, we believe that investor concerns on the debt of the company
have brought the stock to rather cheap valuations, at 1.5x EV/ Sales
FY13E. We believe TV 18 is exposed to various positives, including
changes in regulatory environment (mandatory digitization) and longterm
scale up in subscription revenues (as long as Colors holds up to a
significant position in Hindi GEC sweepstakes). While the holding
company's debt, at Rs 14.3 Bn, is a matter of concern, we think there is
merit in the management's belief that the company's assets are top-ofthe
class, and current losses are not a reflection of their valuation.
q While recognizing that there may be significant near-term risks to an investment
in TV18 Broadcast on account of earnings , we also believe that
an asset view of the company suggests particularly weak valuations and
significant pessimism, at EV/ Sales of 1.5x FY13E. We are attracted by the
potential for the stock to provide large returns, if concerns on debt of
the parent subside (likely, given pressure on the management to act towards
monetizing assets), or if Colors is able to ramp up its ratings post
the storm that KBC has generated. Earnings drivers may emerge too, if
the company's losses from movie business (Rs 200 mn in 2QFY12) reduce
in the coming quarters. We upgrade the stock to BUY with a (12-month,
DCF - based) price target of Rs 65.

Bharat Forge: In-line quarter :: Kotak Sec

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


Bharat Forge (BHFC)
Automobiles
In-line quarter. Bharat Forge standalone net profit was in line with our estimates while
consolidated profit was 7% below our estimates due to lower-than-expected subsidiary
profits. Strong growths in exports and non-auto business were the key positives from
the result while domestic commercial vehicle revenues declined by 7% qoq, indicating
moderate growth for commercial vehicles in the coming quarter. We maintain our ADD
rating but revise our target price to Rs315 (from Rs320 earlier).

Shriram Transport: Hitting rough weathers :: Kotak Sec

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


Shriram Transport (SHTF)
Banks/Financial Institutions
Hitting rough weathers. Shriram Transport (STFC) reported PAT of Rs2.99 bn (stable
yoy and 17% below estimates) on the back of higher provisions even as loan growth
was stable at 20%. STFC’s provisions increased 87% yoy in 2QFY12 due to 9% qoq
increase in gross NPLs and large write-offs from stressed portfolio. We are reducing our
estimates to factor lower growth and higher credit cost. Retain REDUCE with price
target of Rs630 (Rs700 earlier).

Buy ALLAHABAD BANK ; TARGET PRICE: RS.225 :: Kotak Sec

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


ALLAHABAD BANK
PRICE: RS.169 RECOMMENDATION: BUY
TARGET PRICE: RS.225 FY13 P/E: 4.0X, P/ABV: 0.8X
Overall Q2FY12 numbers better than our expectations
q Net interest income (NII) grew 36.0% in Q2FY12 on back of 34 bps expansion
in NIM (YoY), despite moderate loan growth (16.4% YoY). NIM came
at 3.68% during Q2FY12, ahead of our expectations on back of sharper
rise in blended yield on assets (182 bps YoY) vis-à-vis 133 bps rise in cost
of funds.
q However, muted non-interest income (decline of 10.3%) and Rs.824 mn
investment depreciation during Q2FY12 (as against Rs.36 mn in Q2FY11),
somewhat moderated the net profit growth which came at 21.2% YoY
(Rs.4.88 bn).
q Loan book grew at moderate pace (16.4% YoY) due to 7.0% QoQ decline
in agri portfolio; while MSME and retail segments grew at 73.0% and
20.4%, respectively. Deposit mobilization has been strong at 25.0% YoY
with some decline in CASA share (~400 bps YoY); C/D ratio is also down
to 68.2% at the end of Q2FY12.
q Asset quality saw marginal spike as the bank has completely migrated to
system based NPA recognition system. Slippage came at 2.2% (annualized)
during Q2FY12 as against 0.6% witnessed during Q1FY12. In percentage
terms, asset quality is comfortable - gross NPA and net NPA
stand at 1.77% and 0.69%, respectively.
q We are modeling earnings to grow 19.5% CAGR during FY11-13E, while
return ratios are also expected to be healthy (RoE: ~21% during FY12-
13E). At the CMP of Rs.169, the stock is trading reasonable at 4.0x its
FY13E earnings and 0.8x its FY13E ABV. We are maintaining BUY rating
on the stock with revised TP of Rs.225 (Rs.248 earlier) based on 1.0x of its
FY13E adjusted book value.

JSW Energy: Wager gone awry :: Kotak Sec

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


JSW Energy (JSW)
Utilities
Wager gone awry. JSW Energy’s reported loss for 2QFY12 reflects our long-standing
concerns on dependence on market prices for purchase of coal and merchant rates for
sale of power. JSW Energy’s fuel cost rose 26% yoy (Rs3/kwh), while its realizations
came off 14% yoy (Rs3.7/kwh). Further, shutdown of the Barmer facility due to highcost
of generation (and approval of tariffs) further aggravated the reported income.
We continue to remain skeptical on the extant model which is leveraged to spot prices;
maintain REDUCE with a revised target price of Rs53/share (Rs60 previously).

Buy GEOMETRIC ; TARGET PRICE: RS.61 :: Kotak Sec

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


GEOMETRIC LIMITED
PRICE: RS.45 RECOMMENDATION: BUY
TARGET PRICE: RS.61 FY13E P/E: 4.2X
q 2QFY12 results were better than our estimates.
q Volumes grew by about 7%, partly due to the consolidation of Delmia,
which was acquired by 3DPLM, the partly owned subsidiary of Geometric.
Delmia's financials were not disclosed by the company.
q EBIDTA margins improved due to the rupee depreciation, pyramid impact
and better utilization levels.
q The management has indicated that, it is not witnessing any project cancellations
or deferrals. Also, there is demand from both, OEMs and industrial
customers.
q The amount of new orders booked fell marginally to about $8mn during
the quarter ($9.4mn). The company is investing more in business generation
activities, and will continue to do so, we believe.
q Geometric is now focusing on verticalised services and solutions to increase
relevance to customers. Value engineering and cost reduction for
clients are the focus areas.
q The management has indicated greater focus on improving margins
through levers like utilization rates and G&A leverage along with better
utilization of the employee pyramid.
q Consultancy charges may set off any margin improvement over the next
2 - 3 quarters. Company has retained a consulting firm to restructure
business operations.
q We have adjusted earnings estimates to accommodate for 2QFY12 results.
We also introduce FY13E earnings. Our earnings estimates stand at
Rs.9.4 and Rs.10.7, respectively for FY12 and FY13, respectively.
q Our DCF - based price target works out to Rs.61 (Rs.67 earlier), based on
FY13E earnings. We upgrade the stock to BUY based solely on valuations.
q Further signs of stability and sustainability in the revenue profile and an
improvement in the margin profile of Geometric will make us more bullish
on the stock. Our exit multiple works out to 6x FY13E EPS.

Buy IDFC; TARGET PRICE: RS.165::Kotak Sec,

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


IDFC
PRICE: RS.122 RECOMMENDATION: BUY
TARGET PRICE: RS.165 FY13E P/E: 10.2X; P/ABV: 1.3X
Q2FY12: Core earnings in line; however, strong capital gains
aided overall bottom-line growth.
q NII grew 32.9% YoY to Rs.4.97 bn during Q2FY12 on back of strong treasury
NII (Rs.590 mn in Q2FY12 as against Rs.150 mn in Q2FY11) along
with healthy growth in infrastructure segments (22.0% YoY). Net income
was up 59.5% YoY mainly aided by capital gains (Rs.2.59 bn in Q2FY12
as against Rs.200 mn in Q2FY11).
q Business momentum has been moderating since Q3FY11; during Q2FY12,
sanctions and disbursements were down by 63% and 68%, respectively.
Loan book witnessed ~14% YoY growth (4.8% QoQ); sequentially it
came slightly better than last quarter (Q1FY12) when it had remained
flat. Energy segment remained the main contributor to overall disbursement
(44%).
q Average spread (12 months rolling basis) improved ~10bps to 2.3% during
Q2FY12, however, it was flat YoY. Non-interest income was strong
and aided overall bottom-line growth on back of strong capital gains
(Rs.2.57 bn in Q2FY12 as against Rs.200 mn in Q2FY11).
q At CMP, IDFC is trading at reasonable valuation (1.3x its FY13E adjusted
book value). We maintain BUY on the stock with revised TP of Rs.165
(Rs.175 earlier) based on SOTP methodology where core business is valued
at Rs.140 (1.5x FY13 ABV) and Rs.25 for its subsidiaries and other
investments.

Accumulate VOLTAMP; TARGET PRICE: RS.540 :Kotak Sec,

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


VOLTAMP LTD
PRICE: RS.499 RECOMMENDATION: ACCUMULATE
TARGET PRICE: RS.540 FY13E P/E: 9.8X
Voltamp numbers are in line with our expectations. The Transformer
manufacturing sector has been going through a continued phase of margin
pressure and subdued demand conditions. In general working capital cycle
has gone up thus constraining cash flow. The distress in the industry is
likely to persist in the near-to-medium term given moderating investments
in power and industrial sector. We maintain Accumulate on the stock.

Lupin: Lower margin leads to PAT miss :: Kotak Sec

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


Lupin (LPC)
Pharmaceuticals
Lower margin leads to PAT miss. Despite sales being in line with our estimate, PAT
adjusted for research income declined 5% yoy to Rs2 bn due to lower EBITDA margin at
17.3%, down 220 bps yoy. We, however, expect a better 2HFY12E on account of
continuing sales momentum in India/ROW and US product launches. We lower our
FY2012E EPS by 5% to Rs21.4 due to lower margin and retain FY2013E EPS at Rs26.3.
We expect muted EPS growth (ex-research income) of 4% in FY2012E due to lower
margin and increase in tax rate; however, expect EPS growth of 23% in FY2013E. We
value Lupin at 20X FY2013E EPS. Maintain ADD with PT at Rs530 (unchanged).

Hindalco Industries: Good quarter neutralized by guidance cut :: Kotak Sec

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


Hindalco Industries (HNDL)
Metals & Mining
Good quarter neutralized by guidance cut. Novelis reported 2QFY12 adjusted
EBITDA of US$301 mn (+3.8% yoy), ahead of our estimate. Rolled product shipments
declined 2.3% yoy on slowdown in key segments. Novelis has cut FY2012E adjusted
EBITDA guidance by 4% to US$1.1-1.15 bn. Novelis retained operating cash flow and
free cash flow guidance for the year. We will build in revised numbers post Hindalco
earnings on November 10, 2011. We maintain ADD rating on inexpensive valuations.

State Bank of India: Focusing on profits :: Kotak Sec

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


State Bank of India (SBIN)
Banks/Financial Institutions
Focusing on profits. SBI 2QFY12 earnings reflect the underlying pressure to generate
higher profits. Lower fees, treasury gains and higher slippages are the pressure points
while NIMs, stable costs and lower provisions seem to be the few avenues. The bank is
in a dilemma, till it gets comfort on capitalization, as slippages are high and coverage
ratio declines to drive higher earnings. Trends on slippages over the next few quarters
remain the key focus area. Maintain BUY with TP of `2,600 (from `2,750 previously)
factoring earnings revisions.

Economy: Twin deficit concerns back on the radar :: Kotak Sec

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


Economy
‘Twin deficit’ concerns back on the radar. The latest data points on the fiscal and
trade balance situation have raised concerns regarding the weakening macro conditions
of India, apparent in the risks emerging out of the ‘twin deficit’ problem. Given the
emerging risks of shortfalls in revenue collections—both on the tax and non-tax sides,
the government is expected to slip on its fiscal deficit targets for FY2012E. We expect
that the fiscal challenges could continue into FY2013E as well. The trade deficit has also
been widening and leading to an emerging debate of a ‘twin deficit’ problem in India.
In an atmosphere of global risks, any adverse change in market sentiments could lead
to a sharp depreciation of the currency, high interest rates, low private and public
investments and thus hurting growth.

Buy Simplex Infrastructures - 2QFY2012 Result Update Angel Broking

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


For 2QFY2012, Simplex Infra’s (Simplex) numbers came above our expectations
mainly due to higher top-line growth. At the end of the quarter, the company’s
order book stood at `15,034cr (3.0x FY2011 revenue). Simplex reported order
inflows of `1,949cr for the quarter, up 123.3% qoq and (12.6%) yoy. We have
marginally tweaked our estimates to reflect the weak margins, rising interest rate
scenario, increasing debt levels and weak business environment. However, given
the attractive valuations, we continue to maintain our Buy view on the stock.
Decent show on the numbers front: On the top-line front, Simplex reported
25.7% yoy growth to `1,322cr, higher than our estimate. Revenue growth can
mainly be attributed to 27% business growth on the domestic front, with the
international business lagging behind with 7% growth. EBITDAM dipped by
110bp yoy to 9.0% for the quarter, lower than our estimate, which was also
affected by forex loss of `6.0cr. PAT for the quarter declined by 33.5% yoy to
`17.9cr, above our estimate of `9.6cr.
Outlook and valuation: Simplex is facing slowdown on the international front
and is venturing into newer geographies, leading to stretched working capital
and higher interest cost. Management refrained itself from giving any guidance
and maintained that growth would depend upon the domestic environment.
We are downgrading our target price mainly due to lower PE multiple assigned
to factor in the prolonged problems faced in the business environment, leading
to 1) elongated working capital cycle on account of diversification into newer
geographies and 2) higher interest outflow on account of increased debt levels
and rising interest rates. Our revised target price for the stock is `270 (`299
earlier), based on 9x (earlier 10x) FY2013E earnings. We continue to maintain
our Buy recommendation on the stock.

KEC International - 2QFY2012 Result Update : Angel Broking

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


KEC International’s (KEC) 2QFY2012 results exceeded ours and street’s
expectations on the top-line front, but the company’s performance was very
disappointing on the bottom-line front. Order inflow for the quarter totaled
`1,200cr and order backlog stood at `8,450cr. We have lowered our earnings
estimates by 30.0%/26.7% for FY2012E/FY2013E, respectively, to factor in the
margin contraction and changed business environment. We downgrade the
stock’s rating to Neutral.
Strong execution continues; margin contraction a surprise: Consolidated revenue
grew by 26.2% yoy to `1,263cr (`1,001cr), higher than ours and street’s
estimates. On the EBITDAM front, KEC witnessed a steep contraction to 7.2%
mainly due to high raw-material prices, problems in regions such as Egypt and
Libya, and execution of low-margin orders. Further, higher interest cost and tax
incidence dragged down KEC’s earnings (adjusted), leading to a 55.2% yoy dip to
`21.7cr.
Outlook and valuation: The overall slowdown in the power sector has left
transmission EPC companies to reel under pressure. In addition, competition has
intensified on the domestic front, thereby leading to pricing pressures. This is the
first time KEC has witnessed a sharp margin contraction, which we believe is here
to stay in the coming quarters as well, given its reflection of stress in the business
environment, and thereby putting pressure on earnings growth. Further, lack of
positive news flows (read sector related) would keep the stock rise under check.
Notably, KEC’s stock has fallen by ~28% and underperformed the BSE Sensex by
~24% over the last three months. At the CMP of `57, the stock trades 8.4x and
6.2x, FY2012E and FY2013E, EPS, respectively. Despite attractive valuations,
we downgrade the stock’s rating to Neutral with a fair value of `56.

Buy Graphite India - 2QFY2012 Result Update ::Angel Broking

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


For 2QFY2012, Graphite India’s (GIL) top line came in at `462cr, an increase of
42.5% yoy. EBITDA margin contracted by 970bp yoy to 16.4%. EBITDA declined
by 10.5% yoy to `76cr. PAT declined by 32.4% to `42cr on the back of margin
compression. Going ahead, the scenario is positive for the company, as it has
started steel production again in June 2011 (post the shutdown) and is showing a
strong rising trend. We maintain our Buy recommendation on the stock.
Strong sales growth but margin decline: GIL reported strong sales growth in
2QFY2012. Revenue increased by 42.5% yoy and 44.9% qoq to `462cr. The
graphite and carbon segment posted a 45% yoy increase in revenue to `398cr.
Sequentially also, the increase was very strong, with sales increasing by 46.5% on
the back of strong volume growth. The steel division’s revenue increased by 203%
qoq to `28cr. The company’s OPM declined by 970bp yoy to 16.4% due to
increased raw-material cost and other expenses as a percentage of sales.
Consequently, PAT declined by 32.4% yoy but increased by 13.6% qoq on the
back of higher top line. PAT margin came in at 9.1%, down 250bp qoq and
1,005bp yoy, during the quarter.
Outlook and valuation: We remain positive on the prospects of GIL, owing to
strong demand from steel manufacturers. Realizations are also set to increase, as
global players have hiked their prices recently. Post 2QFY2012, we have tweaked
our numbers slightly, and we expect sales to post a 19.2% CAGR over
FY2011–13E and PAT to witness a 17.7% CAGR over the same period. At the
CMP, the stock is trading at attractive valuations of 0.8x its FY2013E BV,
respectively. We have valued the stock at its five-year median of 1.1x one-year
forward book value to arrive at a target price of `102. We maintain our Buy
recommendation on the stock.

Banks - Worsening NPL gap to prolong underperformance of PSBs: Avendus

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


The large rise in net NPL/networth of PSBs in the Sep11 quarter
overshadows the expansion in their NIM. The NPL gap against PSBs is
now at a 12 quarter high and getting worse. At mid‐Nov, the valuation
gap between Nifty and CNXPSBK is at its highest in eight quarters. The
spurts of outperformance may stay short‐lived; we estimate the
underperformance could extend by up to six more months. The
surprise freeing of savings bank deposit rates in the Oct11 monetary
policy may pull down ROA for all, over the long term. Its medium term
impact may be less stark than implied by early reactions. Pricing is not
the sole influence on growth of savings deposits. The trend in NPLs
may be a stronger influence on valuation than the revisions in policy
rates. BOB and ALBK among PSBs, and HDFCB and IIB, among new
banks, are the preferred stocks over the near term.
Buoyant NPLs pull down Sep11 earnings and worsen the outlook
The gap in the net NPL/networth between PSBs and new banks is currently at
its widest in four years and is rising. PSBs saw a 3.3% sequential rise in the net
NPL/networth to 16.7%, while it remained stable for new banks at 2.9%. The
outstanding gross NPL of PSBs increased by 19% sequentially, against a 2%
increase for new banks. NIM expansion and pre‐provision profit growth of 16%
was offset by c44% rise in NPL provisions. During the past six weeks, consensus
net profit growth of PSBs for FY12 has been lowered by 7% to 15% y‐o‐y.
Underperformance of PSBs may extend for another six months
Oct11 was the worst month for PSBs after May11. The premium of the Nifty
P/E over the CNXPSBK increased by c16% in the past six weeks to c125% at the
end of 17 Nov11. It has stayed above the 12‐month moving average for close to
seven months. Historical precedence suggests the underperformance may
extend for another six months. The Bankex underperformed the Sensex by
2.4% in Oct11 and by 3.5% in Nov11. With a combined weight of c70%, new
banks contributed 91% of the rise in the Bankex in Oct11. The trend reversed in
Nov11, as new banks contributed c79% of the c11% fall in the Bankex.
Early reactions to SB deregulation reversed in the following weeks
In our report dated 25 Oct11, we had stated “we believe banks may follow
different strategies, with banks with a very small franchise in savings deposits
possibly adopting aggressive pricing.” Pricing is not the sole influencer of
savings deposits growth. Deregulation may lead to a fall of up to 25‐bp in the
ROA of all banks. The initial run up in banks with low CASA did not sustain.
Contribution of overseas sources of fund to the commercial sector rises
Loan growth declined by 5.4% in Oct11 to c18.0% y‐o‐y. Overseas sources of
funds offset the fall in the contribution of bank loans. The 11% decline in the
contribution of non‐food loans in the Sep11 quarter to c41% was offset by a
13% rise in the contribution from overseas sources such as ECBs/FCCBs and FDI.
Preferred stocks over the near‐term
BOB, ALBK, HDFCB and IIB are the preferred stocks over the near term.

Sun Pharma:: Q2FY12 – Sun shining brightly •GEPL

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


Q2FY12 – Sun shining brightly
• Sun Pharmaceutical Industries (Sun) reported Q2FY12 numbers that were considerably
better than street estimates. Net Sales registered a 42% growth at `18,946 mn in Q2FY12
against `13,314 mn in Q2FY11 aided by growth in prescription sales in the US. However, the
sales numbers for Q2FY12 include the results of Taro and its subsidiaries and are therefore
not strictly comparable on a Y-o-Y basis.
• EBITDA grew 68% Y-o-Y and 43% Q-o-Q to `7,840 mn. This was mainly due to reduction in
cost of raw materials by 4%. Staff cost rose 87% and Other Expenses rose 40% due to
consolidation of Taro numbers.
• PAT registered growth of 19% at `5,977 mn in Q2FY12 against `5,037 mn in Q2FY11. PAT
growth was muted due to rise in Minority Interest and Tax outgo. Consequently, PAT margin
showed a decline of 628 bps to 32%.
Result Highlights
Taro steals the show
Taro reported stellar figures for the July-September, 2011 quarter. Net Sales increased 34% to
$138 mn for Q3CY11 against $103 mn for Q3CY10. Net Income grew more than three-fold to $59
mn in Q3CY11 against $19 mn in Q3CY11. Cash on books nearly doubled to $162 mn during the
quarter. Improvement in Taro’s financials was led by impressive topline growth, reduction in
SG&A expenses and lower R&D expenses.
USFDA issues getting resolved
During the quarter, company resolved the issues relating to USFDA warning at Caraco’s Cranbury
manufacturing facility. Sun is also working hard to resolve the issues at Caraco’s Detroit plant.
Company remains cash rich but refuses to comment on deployment
Sun continues to hold a huge cash balance of ` 23,112 mn on its books. The time is ripe for Sun
to make a huge acquisition and diversify its product portfolio further. Without giving any clear
cut idea of the same, the management indicated that it was looking at synergetic opportunities
across the globe and would consider any if it looked attractive.
Valuation & viewpoint
At the CMP of `510, Sun Pharma is trading at 21x its consensus FY13E earning estimates. Recent
acquisitions have begun to show positive results for the company although the issue of purchase
of remaining stake in Taro is yet to be resolved. Considering the strong presence of the company
in US and India, huge cash on books and very low debt, the company is expected to continue
with its strong performance in the quarters ahead.

Cox & Kings: HolidayBreak integration key to growth in FY13E •GEPL

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


HolidayBreak integration key to growth in FY13E
• Consolidated revenues grew 27.4% Y-o-Y to `1.37bn in Q2FY12 driven by 24% growth in India
revenues (historically a lean season) and a relatively high 29% growth in Rest-of-World (RoW)
partly due to currency fluctuations.
• Consolidated EBITDA grew by a muted 11.5% due to `544 mn in Q2FY12 driven by 20% growth
in India EBITDA and 7% increase in RoW. With a 11.5% growth in EBITDA, a 41% rise in
depreciation, 16% rise in interest cost and a higher tax rate (30.7% in Q2FY12 as compared
to 25% in Q2FY11), the company’s PAT de-grew by 20.4% to `276 mn.
Result Highlights
Strong traction across the globe except Japan
Consolidated revenues grew 27.4% Y-o-Y to `1.37bn in Q2FY12 driven by 24% growth in India
revenues (historically a lean season) and a relatively high 29% growth in Rest-of-World (RoW)
partly due to currency fluctuations. The RoW growth would have been much higher had there not
been a 50% Y-o-Y decline in Japan’s revenues which were in line with expectations. The India
business contributed 40% to the total revenues with UK (23%), Australia (15%), Dubai (8%), and
HolidayBreak (4%) being the other major contributors.
Sharp margin decline in RoW while India margins declined marginally
Consolidated EBITDA grew by a muted 11.5% due to `544 mn in Q2FY12 driven by 20% growth in
India EBITDA and 7% increase in RoW (on account of transfer costs for Middle East travelers to
other destinations). Consequently, consolidated EBITDA margin declined 570bps Y-o-Y to 39.8%.
India accounted for 38% of consolidated EBITDA compared to 36% in Q2FY11.
PAT de-grew by 20% led by higher tax rates and interest costs
With a 11.5% growth in EBITDA, a 41% rise in depreciation, 16% rise in interest cost and a higher
tax rate (30.7% in Q2FY12 as compared to 25% in Q2FY11), the company’s PAT de-grew by 20.4%
to `276 mn.
Valuation & viewpoint
C&K is currently trading at 14.9x FY12E EPS and 9.2x FY13E EPS, a significant discount to its
historical one-year forward P/E band. We believe the discount was mainly due to a) decline in
return ratios due to huge cash on the books and b) uncertainty with respect to the impact of
acquisitions on the company’s future earnings. However, in view of a) the strong demand
visibility with 20.1% earnings CAGR in the next two years, b) the strong probability of an
improvement in return on capital in view of successful track record of past acquisitions, and c)
recent price correction, we expect the stock to perform well in the near future.

Buy CESC - 2QFY2012 Result Update :: Angel Broking

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


For 2QFY2012, CESC posted a 26.5% yoy decline in its net profit on account of
customers being billed under existing tariff, as WBERC’s tariff approval for
FY2012 has been delayed. Although the current tariff provisions allow the hike in
fuel costs to be passed on automatically, CESC has to obtain WBERC’s orders for
passing on the additional fixed costs. However, the company would be
recovering higher tariff (adjusting for additional fixed costs incurred) in the
subsequent quarters with retrospective effect for 1HFY2012 after obtaining new
orders. On the retail business front, per sq. ft. sales of Spencer’s increased to
`1,066/month in 1HFY2012 (13% higher on a yoy basis). Store level EBITDA per
sq. ft. stood at `31 for 1HFY2012. We maintain our Buy view on the stock.
OPM down by 801bp yoy to 19.8%: CESC registered 12.2% yoy growth in its
standalone top line to `1,223cr, aided by 5% growth in sales volume and higher
fuel cost, which is a pass-on. The company’s OPM fell by 801bp yoy to 19.8%
because of lower realization due to delay in grant of tariff approval. The company
had cost adjustment of `67cr included in other expenses during the quarter as
against negative `217cr in 2QFY2011, resulting in operating profit declining by
20.1% to `242cr.
Valuation: We expect CESC’s standalone top line and bottom line to grow at a
CAGR of 10.3% and 4.0%, respectively, over FY2011–13E. At the CMP, the stock
is trading at 6.3x FY2013E EPS and 0.6x FY2013E P/BV. We have assigned 0.85x
FY2013E P/BV multiple to the company’s power business, considering its low RoE,
and have arrived at a value of `357/share. We have valued the retail business
and real estate business at `11/share each. We maintain our Buy view on the
stock with an SOTP-based target price of `379.

Balanced Mutual Funds - Equity oriented

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


Greetings from Integrated.
As the name suggests, this category of funds invests in both the asset classes - equity & debt. At least 65% will be invested in equity and the remaining will get invested in debt. You are getting a ready made portfolio that invests between equity and debt  & need not worry on rebalancing the portfolio as the same is taken care by the professional fund manager.

As for as taxation goes, these funds will get the treatment of an equity fund. There is no dividend distribution tax & no long term capital gain tax if the units are sold after 1 year.
 
The best of Balanced Funds are covered here:
 
Fund NameLaunch DateNAV As on 02.11.2011 (Rs.)Return as a % as on 02.11.2011Value Research Rating
3 Yrs5 YrsSince Inception
Birla Sun Life 95 FundFeb-1995300.7627.0411.6622.86****
Canara Robeco BalanceJan-199360.3825.3910.0411.75****
DSP BlackRock Balanced FundMay-199963.6921.3311.5816.04****
HDFC Balanced FundAug-200056.0629.8412.0716.72*****
HDFC Prudence FundJan-1994206.7331.8313.6320.56*****
Reliance Regular Savings Fund - Balanced PlanMay-200520.9926.3213.1912.28****
Tata Balanced FundOct-199581.7525.9411.7616.17****
 

Rallis India - 2QFY2012 Result Update:: Angel Broking

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


For 2QFY2012, Rallis India (RAIL) reported 18.4% growth in its net sales.
However, net profit growth came in almost flat. We expect RAIL to register a
CAGR of 20% and 23% in its net sales and profit over FY2011-13, respectively.
We remain Neutral on the stock.
Robust growth on the sales front: RAIL’s revenue for the quarter grew by 18.4%
yoy to `430cr. Exports growth came in at 25% yoy and domestic sales stood at
12% yoy. However, the company witnessed a significant erosion of 292bp yoy in
its gross margin to 39.0%. Further, staff cost grew by 19.9% yoy. Consequently,
OPM declined by 250bp yoy to 20.5% and EBITDA grew only by 5.5% yoy. This
resulted in flat growth in net profit to `58.7cr.
Outlook and valuation: Management is confident about the prospects for the
agrochemicals industry. The company expects to outperform the industry, given its
product pipeline. Overall, we expect RAIL to register a CAGR of 20% and 23% in
its net sales and profit over FY2011-13, respectively. At current levels, the stock is
trading at fair valuations of 17.3x FY2013E EPS. Hence, we maintain our Neutral
recommendation on the stock.

SpiceJet - 2QFY2012 Result Update:: Angel Broking

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


For 2QFY2012, SpiceJet’s net sales grew by 22.0% yoy to `766cr. EBITDA margin
came in at negative 30.2%. At the EBITDA level, the company witnessed a loss of
`232cr. Consequently, the company reported net loss of `240cr during the
quarter. We remain Neutral on the stock.
Strong top-line growth, while margin declines: SpiceJet reported strong growth of
22.0% yoy on the back of capacity additions during the year. EBITDAR margin
declined by 2,947bp yoy to negative 12.3% and EBITDA margin declined by
3,081bp yoy to negative 30.2%, owing to higher fuel cost during the quarter.
The company could not raise ticket prices as much as fuel cost due to stiff
completion from FCC players, who were reducing prices to increase load factors
and gain market share. The company registered loss of `240cr in 2QFY2012
compared to profit of `10cr in 2QFY2011.
Outlook and valuation: SpiceJet currently has a fleet of 30 aircraft and will add
another two Boeing aircraft, which will take its Boeing capacity to 32 aircraft by
FY2012. The company will also add 11 Bombardier aircraft by the end of
FY2012, starting from September this year. In FY2013, the company will further
add five Boeing aircraft and four Bombardiers. By the end of FY2013, the total
tally would be 37 Boeings and 15 Bombardiers as per current expansion plans.
We expect net sales to post a 36.8% CAGR to `5,489cr over FY2011–13. Owing
to higher ATF prices and intense competition, we have a cautious view on the
sector and, thus, remain Neutral on the stock.

Buy Corporation Bank- 2QFY2012 Result Update.. Angel Broking

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


For 2QFY2012, Corporation Bank registered net profit growth of 14.0% yoy to
`401cr, above our estimate of `349cr, mainly on account of better-thanexpected
treasury income and a lower effective tax rate than built-in by us. We
recommend Buy on the stock.
Advances growth healthy; Asset quality surprises negatively: During 2QFY2012,
the bank’s advances increased by 17.0% yoy to `81,634cr, while deposits grew by
healthy 24.4% yoy to `120,613cr. Current account deposits witnessed high traction
during the quarter, growing by 12.3% qoq (2.6% yoy), while saving account growth
was moderate at 2.7% qoq (12.1% yoy). CASA ratio managed to improve by 75bp
to 21.8%. The bank’s yield on advances grew sequentially by 60bp; however, cost
of deposits also increased by 29bp qoq, leading to reported NIM remaining flat at
2.4%. During 2QFY2012, other income increased by 76.3% yoy to `399cr, driven
by strong treasury gains (`123cr in 2QFY2012 compared to `4cr in 2QFY2011).
The bank surprised negatively on the asset-quality front, with absolute gross and net
NPAs rising sharply by 27.3% qoq and 81.0% qoq. Consequently, gross and net
NPA ratios deteriorated to 1.3% (from 1.1% in 1QFY2012) and 0.9% (from 0.5% in
1QFY2012), respectively. Slippages for the quarter stood at `510cr (annualized
slippage ratio of 2.3% compared to 0.8% in 1QFY2012). Management attributed
the rise in slippages to system-based NPA recognition and sounded confident of
stronger recoveries going ahead in 2HFY2012.
Outlook and valuation: The bank’s low CASA ratio (~22%) has contributed to
higher margin pressures, given the prevailing high interest rates. However, on the
flip side, the bank would be less impacted by savings deregulation and also
peaking of interest rates bodes well for it. Currently the stock is trading at 0.7x
FY2013E ABV, which we believe provides a margin of safety from current macro
headwinds. Also, the key positive for the bank is its proactive investment in modern
distribution and payment systems, which has led to consistently faster CASA growth
compared to peers. We value the bank at 0.8x FY2013E ABV and recommend a
Buy rating on the stock with a target price of `498.

Annual Report Analysis - Jaiprakash Associates ::Edelweiss,

Please Share:: Bookmark and Share India Equity Research Reports, IPO and Stock News
Visit http://indiaer.blogspot.com/ for complete details �� ��


Jaiprakash Associates’ (JPA) FY11 annual report highlights that revenue and profitability surged on back of the real estate/ infrastructure segment; however, this also led to an increase in debtors exceeding six months. Profit on sale of shares in subsidiary and charging of redemption premium on NCDs/FCCBs through reserves resulted in higher reported profitability. With significant committed capex of ~ INR 503  bn and high debt-equity at 4.1x,  we believe asset/ treasury share monetisation and equity dilution hold the key for funding future capex.  

Revenue jump driven by real estate/ infra segment…
·         JPA revenue and EBIDTA surged from INR 65.2 bn and INR 21.9 bn, respectively, in FY10 to INR 112.6 bn and INR 47.3 bn, respectively, in FY11. The jump was primarily on back of real estate/ infrastructure segment revenue catapulting from INR 6.8 bn in FY10 to INR 42.8 bn in FY11.
… However, cash flow remained subdued
·         Cash flow from operations post interest remained subdued at negative INR 0.4 bn despite a reported PBT of INR 30.9 bn.
·         Debtors exceeding six months jumped significantly from INR 4.2 bn in FY10 to INR 17.0 bn in FY11
Redemption premium on NCDs/ FCCB kept off P&L
·         During FY11, JPA charged redemption premium of INR 2.9 bn (9.4% of PBT) on debentures directly through reserves.
·         As at FY11 end, the company has outstanding two tranches of FCCB of INR 25.1 bn, also, JPVL, a subsidiary had outstanding FCCB of INR8.9 bn. The redemption premium has been charged to reserves; had the company charged the same through P&L on YTM basis, PBT for the year would have been lower by INR 2.0 bn (6.5% of PBT).
·         Total interest cost incurred for FY11 stood at INR 42.3 bn (excl. redemption on FCCB/ NCDs), of which INR 25.6 has been capitalised.
Jaypee Infratech IPO boosts profit / networth
·         During FY11, Jaypee Infratech (JPI), a subsidiary, had made a IPO by issuing 222.9 mn equity shares of INR 10 each at a premium of INR 92/ share.JPA sold 60 mn equity shares of JPI in the IPO and recognised a profit of INR 5.1 bn (16.5% of PBT). 
·         Capital reserve during FY11 increased by INR 6.3 bn which we believe is primarily on account of deemed divesture gains of JPI IPO.